Leerink launched coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with an “outperform” rating and $23 price target. The stock closed at $16.11 on August 25.Read More
Ladenburg Thalmann launched coverage of Reata Pharmaceuticals (NASDAQ:RETA) with a “buy” rating and price target of $55. The stock closed at $21.21 on April 12.Read More
Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular endothelial growth factor (VEGF) trap, aflibercept, for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases.
Regeneron’s aflibercept has been approved by the FDA for certain indications under the brand name, EYLEA.Read More
H.C. Wainwright initiated coverage of Nabriva Therapeutics (NASDAQ:NBRV) with a “buy” rating and $16 price target. The stock closed at $7.92 on Wednesday.
Originally spun-off from Sandoz, Austria-based Nabriva has in-house expertise and broad, wholly-owned IP protection in the development of a novel pleuromutilin class of antibiotics.Read More
Roth Capital Partners launched coverage of Neuralstem (NASDAQ:CUR) with a “buy” rating and price target of $1.20. The stock closed at 25 cents on Friday.
Analyst Joseph Pantginis writes that Neuralstem has undergone a major restructuring and “we believe new management has righted the ship as it is now focused on small molecule approaches to neurological disorders.”Read More
H.C. Wainwright launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and price target of $5. The stock closed at $1.43 on Tuesday.
Aviragen is a developing three direct-acting antiviral (DAA) compounds, each in Phase 2 development, including oral vapendavir, which targets human rhinovirus (HRV), causing the common cold; oral BTA585, which targets respiratory syncytial virus; and BTA074, which is a topical targeting human papillomavirus for condyloma.Read More
Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday.
Exelixis is developing small molecule therapies for the treatment of cancer and is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases.Read More